Ciclesonide

Mechanism :

Ciclesonide is a nonhalogenated, glucocorticoid prodrug that is hydrolysed to the pharmacologically active metabolite des-ciclesonide following administration. Des-ciclesonide has a high affinity for the glucocorticoid receptor and exhibits anti-inflammatory activity.

Indication :

• Asthma

Contraindications :

Hypersensitivity to ciclesonide or any component of the formulation; status asthmaticus or other acute asthma episodes requiring intensive measures.

Dosing :

Adverse Effect :

Headache, nasopharyngitis, facial edema, dizziness, fatigue, voice disorder, urticarial, gastroenteritis, oral candidiasis, influenza, arthralgia, URTI, paradoxical bronchospasm.

Interaction :

Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypocalcemic effect of Amphotericin B.
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.
Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin.
Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypocalcemic effect of Loop Diuretics.
Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypocalcemic effect of Thiazide and Thiazide-Like Diuretics.

Hepatic Dose :